AFU can effectively distinguish PCa from patients with gray-zone PSA levels; and lower AFU expression predicates advanced pathological results, poor therapeutic effect, more postoperative residual tumor numbers, and worse prognosis of PCa patients. This evidence concerns the gene KLK3 and neoplasm.